Cargando…
Endocrine therapy: defining the path of least resistance
One of the best-characterized oncogenic mechanisms in breast cancer is the aberrant activation of phosphatidylinositol-3-kinase, protein kinase B, and mammalian target of rapamycin signaling. In both endocrine-resistant disease and breast cancer stem cells, this is commonly caused by specific geneti...
Autores principales: | Stone, Andrew, Musgrove, Elizabeth A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053240/ https://www.ncbi.nlm.nih.gov/pubmed/25928145 http://dx.doi.org/10.1186/bcr3659 |
Ejemplares similares
-
Can Data Sharing Become the Path of Least Resistance?
Publicado: (2016) -
The Path of Least Resistance
por: Jalli, Sandeep S., et al.
Publicado: (2021) -
Estrogen receptor degradation: a CUE for endocrine resistance?
por: Musgrove, Elizabeth A
Publicado: (2011) -
Precision antimicrobial therapeutics: the path of least resistance?
por: Spaulding, Caitlin N., et al.
Publicado: (2018) -
DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer
por: Stone, Andrew, et al.
Publicado: (2015)